

<b>INFORMATION DISCLOSURE CITATION</b>  PTO-1449				ATTY. DOCKET NO. A-55320-2/RFT/MTK		SERIAL NO. 08/630,383	
				APPLICANT POULETTY et al.			
				FILING DATE April 10, 1996		GROUP 1816	

OIA  
FEB 12 1998  
PATENT & TRADEMARK OFFICE 101


U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	

FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
ms	A	91/07418	30.05.91	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
ms	B	Lussow, A.R., et al. "Targeting of Activated T-Cells with Natural Cytotoxic Antibodies via an IL2-Hapten Conjugate Prolongs Graft Survival", <i>Transplantation Proceedings</i> , Vol. 28, No. 2, pp.571-572 (April 1996).
	C	Litton, M.J., et al., "Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma", <i>Eur. J. Immunol.</i> , Vol. 26, pp. 1-9 (1996).
	D	Lussow, A.R., et al., "Redirecting Circulating Antibodies via Ligand-Hapten Conjugates Eliminates Target Cells in Vivo", <i>Journal of Immunotherapy</i> , Vol. 19(4), pp. 257-265 (1996).
	E	Saha, B., et al., "Toxic Shock Syndrome Toxin-1-Induced Death is Prevented by CTLA4Ig <sup>1</sup> ", <i>Journal of Immunology</i> , pp.3870-3875 (1996).
	F	Kuge, S., et al. "Superantigen-Induced Human CD4 + Helper/Killer T Cell Phenomenon", <i>Journal of Immunology</i> , pp.1776-1785 (1995).
	G	Lando, P.A., et al., "T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens", <i>Cancer Immunol Immunother</i> , Vol. 36, pp. 223-228 (1993).
	H	Lussow, A.R., et al., "Targeting of Antihapten Antibodies to Activated T Cells via an IL-2-Hapten conjugate Prolongs Cardiac Graft Survival <sup>1</sup> ", <i>Transplantation</i> , Vol. 62, No. 12, pp. 1703-1708 (December 27, 1996).

EXAMINER	DATE CONSIDERED
ms	1/23/2001

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
8085 1449A.FRM (8/95)

<b>INFORMATION DISCLOSURE CITATION</b>  PTO-1449				ATTY. DOCKET NO. A-55320-2/RFT/TAL		SERIAL NO. 08/630,383		
				APPLICANT POULETTY et al.				
				FILING DATE April 10, 1996		GROUP 1644		
<b>U.S. PATENT DOCUMENTS</b>								
EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
<b>FOREIGN PATENT DOCUMENTS</b>								
EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							Yes	No
M	1	0 180 171	5/1986	EP	—	—		
	2	<del>0 352 761</del>	<del>7/1988</del>	<del>EP</del>	—	—		
M	3	0 334 300	9/1989	EP	—	—		
M	4	90/11779	10/1990	PCT	—	—		
M	5	91/01004	1/1991	PCT	—	—		
M	6	88/03566	5/1988	PCT	—	—		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
M	7	Bacha et al., "Interleukin 2 Receptor-Targeted Cytotoxicity," J. Exp. Med., 167:612-622 (1988).						
M	8	Gravelle et al., "The Targeting of CD4+ T Lymphocytes to A B Cell Lymphoma," The Journal of Immunology, 142: 4079-4084 (1989).						
M	9	Staerz et al., "Hybrid antibodies can target sites for attack by T cells," Nature, 314:628-631 (1985).						
M	10	Staerz et al., "Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity," Proc. Natl. Acad. Sci. USA, 83:1453-1457 (1986).						
M	11	Murphy, J.R. "Diphtheria-related peptide hormone gene fusions: A molecular genetic approach to chimeric toxin," Immunotoxins, Frankel, A.E. (ed.), Kluwer Academic Publishers, 1988, 123-140.						
M	12	Martindale, The Extra Pharmacopeia, Reynolds, J. (ed.), The Pharmaceutical Press, 1989, p.1160.						
M	13	Alberts, B. (ed.), Molecular Biology of the Cell, Third Edition, Garland Publishing, 1994, 1169-1170.						
M	14	Oxford Dictionary of Biochemistry and Molecular Biology, Smith, A.D. (ed.), Oxford University Press, 1997, 155,216.						
EXAMINER				DATE CONSIDERED				
				1/23/2004				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

8085 1449A.FRM (8/95)  
1027958

PTO-1449

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.  
A-55320-2/RFT/TAL

SERIAL NO.  
08/630,383

APPLICANT  
POULETTY et al.

FILING DATE  
April 10, 1996

GROUP  
1644

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
RM	1	4,681,760	7/1987	Fathman	—	—	
MB	2	4,675,382	6/1987	Murphy	—	—	
MB	3	4,946,945	8/1990	Wojdani	—	—	

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							Yes	No
MB	4	2-169521	6/2/90	JP <del>unexamined, published</del>	—	—	x	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

RM	5	Berkow et al., The Merck Manual, published by Merck Research Laboratories, 1992, p.353.
MB	6	Tuevefson et al., Imm. Rev. 136:99-109 (1993).
MB	7	Legaard et al., Cellular Immunology, 135:372-382 (1991).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SERIAL NO.  
08/630,383

APPLICANT  
POULETTY et al.

FILING DATE  
April 10, 1996

GROUP  
1644

DEC 05 2000

PTO-1449

## U.S. PATENT DOCUMENTS

[illegible]

RECEIVED

DEC 11 2000

**FOREIGN PATENT DOCUMENTS**

~~TECH CENTER 1600/2900~~

EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							Yes	No
<i>m</i>	1	93/17699	9/1993	PCT <i>we</i>	—	—		
<i>ms</i>	2	95/34321	12/1995	PCT <i>wo</i>	—	—		
<i>me</i>	3	96/35443	11/1996	PCT <i>wo</i>	—	—		
<i>me</i>	4	97/24140	7/1997	PCT <i>wo</i>	—	—		
<i>mi</i>	5	97/37690	10/1997	PCT <i>wo</i>	—	—		
	<del>6</del>	<del>4238416</del>	<del>5/1994</del>	<del>DE</del>				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	

[illegible]

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.